Waters Acquires Thar Instruments
News Feb 06, 2009
Waters Corporation announces acquisition of all the remaining outstanding capital stock of privately held Pittsburgh-based Thar Instruments, Inc., for an undisclosed amount.
Waters® had previously made an equity investment in Thar in June 2007. Thar’s current annual revenues are approximately $18 million, and the acquisition is estimated to be neutral to Waters 2009 earnings.
Considered a leading “green” analytical and purification technology, Thar’s SFC and extraction systems are used to separate, isolate and quantify chemical compounds. The principles of SFC are similar to those of liquid chromatography; however SFC typically uses carbon dioxide as the main mobile phase.
"By combining Thar’s advanced SFC instrumentation with Waters chromatography expertise, Waters is committed to bringing the benefits of SFC to more laboratories for analytical and purification applications worldwide,” said Dr. Rohit Khanna, Vice President, Worldwide Marketing for Waters Division. “Complementing Waters ACQUITY™ UPLC™ environmental position of reduced solvent use without compromised analytical capabilities, SFC expands Waters ‘green’ separation science leadership as customers increasingly demand environmentally friendly options."
Thar products are used in pharmaceutical, life science, chemical and petrochemical companies, as well as government agencies, research institutions and universities. In a world seeking renewable technologies for solving waste and disposal problems, Waters and Thar seek to fill the void with innovative ‘green’ chemistry solutions.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE